(Q30353864)

English

A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

1 reference

based on heuristic

inferred from title

evidence-based medicine

1 reference

based on heuristic

inferred from title

object named as

Leslie Citrome

1

0 references

publication date

1 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

879-911

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

https://scigraph.springernature.com/pub.10.1007/s40263-013-0105-7

0 references

Evidence-based medicine: it’s not just about the evidence

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Evidence based medicine: what it is and what it isn't

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Compelling or irrelevant? Using number needed to treat can help decide

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Asenapine versus olanzapine in acute mania: a double-blind extension study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Lurasidone in schizophrenia: new information about dosage and place in therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Lurasidone for schizophrenia: what's different?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Iloperidone: a clinical overview

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Role of sublingual asenapine in treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Drug safety evaluation of ziprasidone

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Is there a role for 5-HT1A agonists in the treatment of depression?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Using oral ziprasidone effectively: the food effect and dose-response

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Olanzapine-fluoxetine combination for the treatment of bipolar depression

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

“Meta-guidelines” for the management of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0105-7

21 January 2018

Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glutamatergic transmission in schizophrenia: from basic research to clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atypical antipsychotics: matching receptor profile to individual patient's clinical profile

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI

1 reference

https://pubmed.ncbi.nlm.nih.gov/24062193

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40263-013-0105-7

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30353864&oldid=1982361528"